Your session is about to expire
← Back to Search
Opioid Partial Agonist
Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder
Phase 2
Waitlist Available
Led By frances r levin, md
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is comparing an injection to a pill of buprenorphine to help people who use strong opioids like fentanyl. The goal is to see if the injection works better at reducing drug use. Buprenorphine helps by reducing cravings and easing withdrawal symptoms. Buprenorphine is an effective treatment for opioid use disorder, known for its ability to suppress withdrawal and cravings, and has been used in various formulations.
Eligible Conditions
- Opioid Use Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Days of opioid use per week
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: extended-release buprenorphine (BXR)Experimental Treatment1 Intervention
Three extended-release buprenorphine (BXR) injections to be administered roughly 28 days apart. The first and second injection will be 300 mg and the third will be 100 mg.
Group II: sublingual buprenorphine (BSL)Active Control1 Intervention
sublingual buprenorphine (BSL) up to 24 mg will be administered once daily for 12 weeks or length of study participation.
Find a Location
Who is running the clinical trial?
New York State Psychiatric InstituteLead Sponsor
478 Previous Clinical Trials
153,933 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,594 Previous Clinical Trials
3,328,696 Total Patients Enrolled
frances r levin, mdPrincipal InvestigatorNew York State Psychiatric Institute